Reply to Kadri Altundag
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24838
Abstract: We thankKadri for his discussion of our recent article entitled “Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.” The questions posed by Kadri et al question… read more here.
Keywords: patients her2; adjuvant trastuzumab; her2 loss; neoadjuvant chemotherapy ... See more keywords
Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review.
Sign Up to like & getrecommendations! Published in 2019 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2019.02.003
Abstract: OBJECTIVES To systematically review and assess the quality of the economic evidence of adjuvant trastuzumab usage in early breast cancer in Asian countries. METHODS Literature search was performed using 6 electronic databases (PubMed, Scopus, Ovid… read more here.
Keywords: adjuvant trastuzumab; breast cancer; cost; early breast ... See more keywords
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Sign Up to like & getrecommendations! Published in 2019 at "The Lancet"
DOI: 10.1016/s0140-6736(19)30653-1
Abstract: BACKGROUND In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we… read more here.
Keywords: adjuvant trastuzumab; month group; months adjuvant; group ... See more keywords
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
Sign Up to like & getrecommendations! Published in 2019 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-018-0098-y
Abstract: ADJUVANT TRASTUZUMAB One year of adjuvant trastuzumab has been the standard treatment for human epidermal growth factor receptor 2positive (HER2-positive) early breast cancer since the mid2000s. From the outset, the expense and cardiac toxicity associated… read more here.
Keywords: persephone; adjuvant trastuzumab; treatment; trastuzumab ... See more keywords
6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000024995
Abstract: Abstract Background: Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the… read more here.
Keywords: adjuvant trastuzumab; breast cancer; treatment; months adjuvant ... See more keywords
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Sign Up to like & getrecommendations! Published in 2019 at "BMC Health Services Research"
DOI: 10.1186/s12913-019-4715-8
Abstract: BackgroundBreast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment… read more here.
Keywords: her2 positive; adjuvant trastuzumab; trastuzumab; therapy ... See more keywords
Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.10066
Abstract: 10066Background: Cardiac dysfunction may occur in patients (pts) receiving adjuvant trastuzumab-based chemotherapy and long follow-up is required to better understand it. This meta-analysis of 3 ad... read more here.
Keywords: cardiac events; events adjuvant; adjuvant trastuzumab; analysis cardiac ... See more keywords
Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14314
Abstract: Background/Aim: To evaluate the improvement in the prognosis by adjuvant trastuzumab in clinical practice and the risk factors for distant recurrence, we retrospectively investigated the prognosis of HER2-positive early breast cancer in our department before… read more here.
Keywords: her2 positive; positive early; clinical practice; adjuvant trastuzumab ... See more keywords